# Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

> **NCT03170115** · PHASE2 · TERMINATED · sponsor: **Instituto Nacional de Cancer, Brazil** · enrollment: 25 (actual)

## Conditions studied

- Rectal Cancer, Adenocarcinoma
- Locally Advanced Malignant Neoplasm
- Chemoradiation

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03170115
- **Lead sponsor:** Instituto Nacional de Cancer, Brazil
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-30
- **Primary completion:** 2020-01-17
- **Final completion:** 2020-01-17
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Aspirin added to chemoradiotherapy was safe but did not improve response to total neoadjuvant treatment. The study was closed due absence of benefit.
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03170115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03170115, "Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03170115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*